by Maggie Fick

London: Novo Nordisk Wegovy Obesity medication A large study found that 100 mg/ml reduced kidney-related adverse events by 22 percent in overweight and obese people, according to a new analysis published Saturday by the Danish drugmaker.

The analysis, derived from a larger study whose solid results were released by Novo last year, was presented at the European Renal Congress in Stockholm.

“By addressing key markers Kidney health, Semaglutide…may contribute to a significant reduction in the risk of kidney-related complications, including chronic kidney disease and end-stage renal disease,” said Professor Helen M. Colhoun of the University of Edinburgh and lead study author.

A Novo spokesperson said in a statement to Reuters that the new analysis “shows for the first time the benefits of semaglutide 2.4 mg in improving kidney function.” cardiovascular disease And people who are overweight or obese, without diabetes, are a high-risk population who are in greater need of kidney protection.”

This study follows one published in March. de novo study The diabetes drug Ozempic slowed the development of chronic kidney disease in diabetics. Ozempic has the same active ingredient, semaglutide, as Wegovy, which is approved as a treatment for obesity.

The latest data adds to the medical evidence that suggests GLP-1 classThose that suppress appetite by mimicking gut hormones have therapeutic benefits for conditions beyond their initial objectives, type 2 diabetes and weight loss.

The new analysis found that semaglutide caused a slower decline in a certain measure of kidney function, known as eGFR (estimated glomerular filtration rate), particularly in people who already had kidney problems.

The analysis found that there was also a significant reduction in urinary albumin-to-creatine ratio (UACR), another important indicator of kidney health.

“There was no increased risk,” regardless of kidney function at the start of the study acute kidney injury was associated with semaglutide”, it found.

The analysis examined data from a large trial called SELECT by Novo Nordisk. Its preliminary results were published in August.

In a trial of 17,604 patients, Wegovy was tested not for weight loss or kidney function, but for its heart-protective benefits in overweight and obese patients who already had heart disease but not diabetes.

The analysis, published on Saturday, comes a day after Novo presented detailed results from a separate late-stage trial showing that its diabetes drug Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes and reduced the risk of kidney failure, heart problems, stroke and death.

(Reporting by Maggie Fick; Editing by Frances Kerry)